Emerging bedaquiline-resistant tuberculosis.
作者信息
Lange Christoph, Vasiliu Anca, Mandalakas Anna M
机构信息
Research Center Borstel, Clinical Infectious Diseases, Borstel, Germany; German Center for Infection Research Tuberculosis Unit, 23845 Borstel, Germany; Respiratory Medicine & International Health, University of Lübeck, Lübeck, Germany; Global TB Program, Baylor College of Medicine and Texas Children's Hospital, Houston, TX, USA.
Global TB Program, Baylor College of Medicine and Texas Children's Hospital, Houston, TX, USA.
出版信息
Lancet Microbe. 2023 Dec;4(12):e964-e965. doi: 10.1016/S2666-5247(23)00321-X. Epub 2023 Nov 3.
Abstract
摘要
相似文献
1
Emerging bedaquiline-resistant tuberculosis.
Lancet Microbe. 2023 Dec;4(12):e964-e965. doi: 10.1016/S2666-5247(23)00321-X. Epub 2023 Nov 3.
2
Bedaquiline-Resistant Tuberculosis Associated with Mutations.
N Engl J Med. 2022 Jan 6;386(1):93-94. doi: 10.1056/NEJMc2103049.
3
Can the addition of verapamil to bedaquiline-containing regimens improve tuberculosis treatment outcomes? A novel approach to optimizing TB treatment.
Future Microbiol. 2015;10(8):1257-60. doi: 10.2217/FMB.15.56. Epub 2015 Jul 30.
4
Minimising the threat of bedaquiline-resistant tuberculosis: better diagnosis as prevention.
Lancet Infect Dis. 2024 Mar;24(3):226-228. doi: 10.1016/S1473-3099(23)00550-9. Epub 2023 Nov 10.
5
[Questions about bivalirudin (infarction) and bedaquiline (tuberculosis)].
Rev Med Suisse. 2013 Nov 13;9(406):2130-1.
6
Multidrug-resistant tuberculosis and bedaquiline.
N Engl J Med. 2014 Dec 18;371(25):2435-6. doi: 10.1056/NEJMc1412235.
7
Multidrug-resistant tuberculosis and bedaquiline.
N Engl J Med. 2014 Dec 18;371(25):2436. doi: 10.1056/NEJMc1412235.
8
Bedaquiline: a novel antitubercular drug for multidrug-resistant tuberculosis.
J Postgrad Med. 2014 Jul-Sep;60(3):300-2. doi: 10.4103/0022-3859.138772.
9
The use of bedaquiline to treat patients with multidrug-resistant tuberculosis and end-stage renal disease: A case report.
Int J Infect Dis. 2018 Nov;76:88-90. doi: 10.1016/j.ijid.2018.09.009. Epub 2018 Sep 19.
10
Bedaquiline for the treatment of drug-resistant tuberculosis.
Expert Rev Anti Infect Ther. 2015 May;13(5):535-53. doi: 10.1586/14787210.2015.1021785. Epub 2015 Mar 22.
引用本文的文献
1
Identification of novel leucyl-tRNA synthetase inhibitors with antibacterial activity.
Future Med Chem. 2025 Apr;17(7):757-765. doi: 10.1080/17568919.2025.2485673. Epub 2025 Apr 21.
2
15-year trends in efficacy and effectiveness of treatment outcomes in drug-resistant pulmonary TB.
IJTLD Open. 2025 Apr 9;2(4):187-198. doi: 10.5588/ijtldopen.24.0620. eCollection 2025 Apr.
3
Weaponizing the bystander T cell army to fight tuberculosis.
Proc Natl Acad Sci U S A. 2024 Jun 4;121(23):e2407559121. doi: 10.1073/pnas.2407559121. Epub 2024 May 30.
4
Multidrug-resistant tuberculosis.
Nat Rev Dis Primers. 2024 Mar 24;10(1):22. doi: 10.1038/s41572-024-00504-2.
本文引用的文献
1
Bedaquiline resistance in patients with drug-resistant tuberculosis in Cape Town, South Africa: a retrospective longitudinal cohort study.
Lancet Microbe. 2023 Dec;4(12):e972-e982. doi: 10.1016/S2666-5247(23)00172-6. Epub 2023 Nov 3.
2
Bedquiline Resistance Mutations: Correlations with Drug Exposures and Impact on the Proteome in M. tuberculosis.
Antimicrob Agents Chemother. 2023 Jul 18;67(7):e0153222. doi: 10.1128/aac.01532-22. Epub 2023 May 31.
3
Treatment Strategy for Rifampin-Susceptible Tuberculosis.
N Engl J Med. 2023 Mar 9;388(10):873-887. doi: 10.1056/NEJMoa2212537. Epub 2023 Feb 20.
4
Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis.
Lancet. 2022 Feb 12;399(10325):629-655. doi: 10.1016/S0140-6736(21)02724-0. Epub 2022 Jan 19.
5
Emergence of bedaquiline resistance in a high tuberculosis burden country.
Eur Respir J. 2022 Mar 24;59(3). doi: 10.1183/13993003.00621-2021. Print 2022 Mar.
6
Design of Multidrug-Resistant Tuberculosis Treatment Regimens Based on DNA Sequencing.
Clin Infect Dis. 2021 Oct 5;73(7):1194-1202. doi: 10.1093/cid/ciab359.
7
Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis.
Lancet Respir Med. 2020 Apr;8(4):383-394. doi: 10.1016/S2213-2600(20)30047-3. Epub 2020 Mar 17.
8
Acquisition of Cross-Resistance to Bedaquiline and Clofazimine following Treatment for Tuberculosis in Pakistan.
Antimicrob Agents Chemother. 2019 Aug 23;63(9). doi: 10.1128/AAC.00915-19. Print 2019 Sep.
9
Efficacy and safety of delamanid in combination with an optimised background regimen for treatment of multidrug-resistant tuberculosis: a multicentre, randomised, double-blind, placebo-controlled, parallel group phase 3 trial.
Lancet Respir Med. 2019 Mar;7(3):249-259. doi: 10.1016/S2213-2600(18)30426-0. Epub 2019 Jan 7.
10
Effect of bedaquiline on mortality in South African patients with drug-resistant tuberculosis: a retrospective cohort study.
Lancet Respir Med. 2018 Sep;6(9):699-706. doi: 10.1016/S2213-2600(18)30235-2. Epub 2018 Jul 11.
Zotero 插件